Additional experiments have demonstrated that the pharmacological inhibition of mTOR with rapamycin (RAPA) not only blocks the UBE2O-driven upregulation of p-mTOR, but also markedly suppresses the proliferative capacity and migratory potential of HCC cells [24]. Here, MTOR is linked to hepatocellular carcinoma.